Emphysema Imaging
Introduction
Emphysema imaging refers to the use of medical imaging techniques to visualize and characterize emphysema, a chronic lung condition that is a major component of Chronic Obstructive Pulmonary Disease (COPD). COPD is a progressive disease characterized by airflow limitation that is not fully reversible, significantly impacting global health and quality of life. [1]
Biological Basis
Emphysema is pathologically defined by the destruction of the air sacs (alveoli) in the lungs, leading to permanently enlarged airspaces and a loss of elasticity. This structural damage impairs gas exchange and leads to the characteristic symptoms of shortness of breath. Lung function measures, such as forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and their ratio (FEV1/FVC), are used to diagnose COPD and are known to be highly heritable traits. [2]
Genetic factors play a significant role in an individual's susceptibility to COPD and emphysema. While alpha-1-antitrypsin deficiency, caused by mutations in the SERPINA1 gene, is a well-documented genetic cause, it accounts for a small proportion of cases. [2] Genome-wide association (GWA) studies have been instrumental in identifying additional genetic variants associated with lung function and COPD. For instance, the SERPINE2 gene has been linked to COPD. [3] Other candidate genes investigated for their association with spirometry measures or pulmonary disease include CFTR, members of the Glutathione S-transferase family (GSTO1, GSTO2, GSTM2, GSTT1, GSTT2), surfactant proteins (SFTPA1, SFTPC), extracellular superoxide dismutase (SOD3), interleukin-8 receptor alpha (IL8RA), interleukin-10 (IL10), beta-2 adrenergic receptor (ADRB2), transforming growth factor beta-1 (TGFB1), and the interleukin 6 receptor (IL6R). [2] Single nucleotide polymorphisms (SNPs) within or near these genes are actively studied for their influence on lung health.
Clinical Relevance
Imaging techniques, particularly high-resolution computed tomography (HRCT), are crucial for directly visualizing the extent and distribution of emphysematous changes in the lungs. This allows for a more precise characterization of the disease beyond spirometry alone, aiding in diagnosis, prognosis, and treatment planning. Understanding the genetic underpinnings of emphysema, often identified through GWA studies of lung function, can help identify individuals at higher risk even before symptomatic decline. This genetic information, combined with advanced imaging, holds the potential for personalized medicine approaches, allowing for earlier intervention, targeted therapies, and more effective management strategies for emphysema and COPD patients.
Social Importance
COPD, including emphysema, represents a substantial public health burden worldwide, contributing to significant morbidity, mortality, and healthcare expenditures. [1] Advances in emphysema imaging, coupled with insights from genetic studies, are vital for improving global lung health. By enhancing our ability to detect, characterize, and predict the progression of emphysema, these tools can lead to earlier diagnoses, more effective preventive measures, and optimized treatment regimens. Ultimately, improved understanding and management of emphysema have the potential to reduce the societal impact of COPD, alleviate patient suffering, and extend healthy life spans.
Methodological and Statistical Constraints
Genetic studies investigating complex traits, such as those related to lung function, face inherent statistical challenges that can limit the detection and confirmation of genetic associations. A primary constraint is often the statistical power, which may be insufficient to identify genetic effects that exert only a modest influence on the phenotype, particularly when a large number of genetic markers are tested across the genome. [4] The necessity of applying stringent statistical thresholds to account for extensive multiple testing further reduces the ability to declare genome-wide significance, meaning that genuine associations with smaller effect sizes might go undetected or be dismissed as false positives. [4]
Furthermore, the comprehensiveness of genetic coverage can restrict the discovery process and the ability to replicate prior findings. Early genome-wide association studies, utilizing platforms like the 100K SNP GeneChip, provided only partial coverage of the vast genetic variation within the genome, potentially missing significant genetic variants not present on the array. [5] This limited coverage can hinder the ability to thoroughly investigate candidate genes and makes the replication of novel findings in independent cohorts crucial for validating observed associations, as replication remains the definitive test for the value of such genetic discovery approaches. [4]
Phenotypic Characterization and Generalizability
The precise characterization of phenotypes, particularly those that evolve over time or are subject to measurement variability, presents significant challenges in genetic association studies. For instance, averaging phenotypic measures across multiple examinations, while intended to reduce bias and better represent a trait over time, can introduce misclassification if the examinations span long periods or utilize different equipment. [4] This averaging approach also assumes a consistent genetic and environmental influence across a wide age range, potentially masking age-dependent genetic effects that might otherwise be discernable. [4]
Moreover, the generalizability of findings from specific study populations is a critical consideration. Studies conducted predominantly in cohorts of a particular ancestry, such as individuals of white European descent, may not yield results that are directly applicable to other ethnic groups. [4] This limitation underscores the need for diverse study populations to ensure that identified genetic risk factors are broadly relevant and to explore potential ancestry-specific genetic influences on complex traits. Additionally, conducting only sex-pooled analyses might overlook genetic variants that exhibit sex-specific associations with phenotypes, thereby missing important biological insights. [6]
Environmental Influences and Unexplained Variation
Complex traits are often shaped by intricate interactions between an individual's genetic makeup and their environment, posing a challenge for genetic studies that do not explicitly investigate these interactions. Genetic variants can influence phenotypes in a context-specific manner, with their effects being modulated by various environmental factors. [4] For example, the associations of ACE and AGTR2 with LV mass were reported to vary according to dietary salt intake in one investigation, highlighting the importance of considering gene-environment interactions, which were not typically undertaken in some studies. [4]
Despite the identification of some heritability for many complex traits, a substantial portion of the genetic basis remains unexplained, contributing to what is often termed "missing heritability." While specific genetic causes for conditions like chronic obstructive pulmonary disease have been identified, the underlying genetic risk factors for the majority of cases remain largely unknown. [2] This remaining knowledge gap suggests that numerous other genetic factors, potentially with small individual effects or involved in complex pathways, await discovery, and that comprehensive understanding requires further research, including the exploration of gene-environment interactions and more extensive genomic coverage.
Variants
Genetic variations play a crucial role in an individual's susceptibility to complex diseases, including chronic obstructive pulmonary disease (COPD) and its manifestation as emphysema. Understanding these variants and their associated genes provides insight into the biological pathways that influence lung structure and function, which can be reflected in emphysema imaging. Many genes contribute to the intricate balance of tissue maintenance, immune response, and cellular repair, and single nucleotide polymorphisms (SNPs) within or near these genes can alter their activity, potentially leading to disease predisposition .
Variants in genes such as OR8B2 and OR8B3 (rs185888204), which encode olfactory receptors, illustrate the broad impact of genetic diversity. While primarily known for their role in the sense of smell, olfactory receptors can also be expressed in non-olfactory tissues where they may influence cellular signaling and inflammatory processes, indirectly affecting pulmonary health. Similarly, DLC1 (Deleted in Liver Cancer 1), associated with rs74834049 and rs75200691, functions as a tumor suppressor by regulating cell growth, migration, and adhesion. Disruptions in these fundamental cellular processes, influenced by genetic variants, can impair the lung's ability to repair itself after injury, contributing to the tissue destruction characteristic of emphysema. [5]
Other genes implicated in maintaining cellular integrity and mediating immune responses include ERCC4 (Excision Repair Cross-Complementation Group 4), near which rs9933712 is located. ERCC4 is vital for DNA repair, and maintaining genomic stability is essential for healthy lung tissue, as environmental stressors can induce DNA damage that, if not properly repaired, may accelerate cellular senescence and tissue degradation seen in emphysema. The chemokine XCL2, near variants like rs75565482 and rs72637224, plays a role in immune cell trafficking and inflammation. Chronic inflammation is a hallmark of emphysema, and genetic variations affecting chemokine activity could modulate the severity of immune responses in the lung, impacting disease progression and the extent of changes visible on imaging. [7]
The SERPINA gene family, which includes SERPINA10 associated with rs45505795, is particularly relevant to pulmonary health. Although SERPINA10 itself is not as widely studied in emphysema as SERPINA1 (alpha-1 antitrypsin), other members like SERPINA1 and SERPINE2 have established associations with chronic obstructive pulmonary disease. [2] Serpins are protease inhibitors that maintain a critical balance with proteases in the lung, protecting tissue from enzymatic degradation. Variants affecting any serpin, including SERPINA10, could tip this balance, leading to unchecked protease activity and the destructive changes seen in emphysema imaging. Furthermore, regulatory RNAs such as LNCAROD (rs139326003) and HHIP-AS1 (rs13141641), an antisense RNA to the HHIP gene, are increasingly recognized for their roles in modulating gene expression. Variants affecting these non-coding RNAs could influence the expression of key genes involved in lung development, repair, and inflammation, thereby contributing to the genetic predisposition to emphysema and its characteristic structural changes. [2]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs185888204 | OR8B2 - OR8B3 | emphysema imaging measurement |
| rs9933712 | ERCC4 - LINC02185 | emphysema imaging measurement |
| rs144442299 | UNC13C | emphysema imaging measurement |
| rs111646341 | LSAMP | emphysema imaging measurement |
| rs74834049 rs75200691 |
DLC1 | gas trapping measurement emphysema imaging measurement |
| rs45505795 | SERPINA10 | forced expiratory volume, response to bronchodilator FEV/FVC ratio, response to bronchodilator emphysema imaging measurement blood protein amount BMI-adjusted hip circumference |
| rs75565482 rs72637224 |
QRSL1P1 - XCL2 | emphysema imaging measurement |
| rs139326003 | LNCAROD | emphysema imaging measurement |
| rs13141641 | KRT18P51 - HHIP-AS1 | forced expiratory volume, response to bronchodilator FEV/FVC ratio, response to bronchodilator emphysema imaging measurement chronic obstructive pulmonary disease emphysema pattern measurement |
| rs12605822 | TWSG1-DT | emphysema imaging measurement |
Clinical Presentation and Functional Assessment
Clinical evaluation for emphysema begins with a thorough assessment of respiratory symptoms, which are often directly related to the extent of emphysema and airway wall thickness.. [8] Historically, clinical assessments have helped distinguish between the emphysematous and bronchial types of chronic airways obstruction.. [9] While physical examination findings are not specific for emphysema alone, they contribute to the overall diagnostic picture of chronic obstructive pulmonary disease (COPD), a condition primarily defined by irreversible airflow obstruction identified through spirometry.. [10] Spirometric measures of lung function are essential for diagnosing COPD, and changes in these measures are associated with the longitudinal progression of emphysema.. [10]
Advanced Imaging and Quantitative Phenotyping
Computed tomography (CT) is the cornerstone imaging modality for diagnosing and quantitatively assessing emphysema, providing detailed insights into its extent and progression.. [10] Quantitative CT measures, which identify low attenuation areas indicative of parenchymal destruction, are valuable diagnostic tools that correlate with respiratory symptoms, lung function decline, and the specific distribution of emphysema.. . . [8], [11], [12] These radiographic phenotypes are also linked to COPD exacerbations and can predict associated risks such as low bone mineral density and lung cancer, underscoring their clinical utility in comprehensive patient evaluation.. . . [13], [14], [15] Quantitative CT measures of emphysema and airway wall thickness vary by sex, age, and smoking status, emphasizing the need for individualized interpretation.. [16]
Genetic and Molecular Biomarkers
Genetic testing and molecular markers are increasingly recognized for their role in understanding emphysema susceptibility and disease progression. Genome-wide association studies (GWAS) have successfully identified specific genetic loci associated with emphysema and airway quantitative imaging phenotypes, indicating a significant genetic component to the disease.. . [17], [18] For example, variants in the BICD1 gene have been associated with emphysema, and DSP variants may relate to longitudinal changes in quantitative emphysema.. . [10], [19] Beyond genetic predisposition, blood tests, such as eosinophil counts, serve as prognostic biomarkers in COPD, offering insights into disease phenotypes that may include emphysema.. [20] Familial aggregation of both airway wall thickening and emphysema in COPD further supports the utility of genetic factors in diagnosis and risk assessment.. [21]
Differential Diagnosis and Diagnostic Challenges
Emphysema, while a key component of COPD, presents a diagnostic challenge because its presence and severity can vary considerably among individuals with similar degrees of airflow obstruction.. [10] Accurate differential diagnosis is crucial to distinguish emphysema from other conditions presenting with similar respiratory symptoms or lung abnormalities. For instance, radiographic emphysema and airflow obstruction are known to be associated with lung cancer, necessitating careful evaluation in at-risk populations to avoid misdiagnosis.. [15] Furthermore, systemic comorbidities such as low bone mineral density and arterial stiffness have been independently linked to emphysema severity, requiring a comprehensive diagnostic approach to identify these associated conditions and guide appropriate management.. . [14], [22]
Pathophysiology of Emphysema and Airflow Obstruction
Emphysema, a significant component of Chronic Obstructive Pulmonary Disease (COPD), is characterized by the progressive and irreversible obstruction of airflow. [2] This condition involves the destruction of the delicate alveolar walls in the lungs, leading to the enlargement of air spaces and a profound loss of elastic recoil, which severely impairs the ability to exhale air efficiently. [2] The functional consequences of this tissue damage are typically assessed by spirometry, measuring parameters such as forced expiratory volume in one second (FEV1) and forced vital capacity (FVC), whose decline over time directly reflects the progression of the disease and the extent of chronic airflow limitation. [2] The disruption of normal lung architecture and mechanics compromises efficient gas exchange, leading to chronic respiratory impairment.
The development of emphysema is largely initiated by chronic exposure to noxious particles and gases, with cigarette smoking being a primary and well-established risk factor. [4] This environmental insult triggers a persistent inflammatory response within the airways and lung parenchyma, setting in motion a complex cascade of cellular and molecular events that culminate in widespread tissue destruction. [2] The ensuing homeostatic disruptions involve an imbalance between destructive and protective cellular processes, leading to the breakdown of essential structural components of the lung. This chronic inflammatory state is not confined to the lungs but can also exert systemic consequences, affecting various other organ systems. [23]
Genetic Predisposition and Molecular Regulation
Genetic factors significantly contribute to an individual's susceptibility to developing emphysema, as evidenced by the high heritability of lung function measures like FEV1 and FVC. [2] Numerous genes have been identified as potential genetic risk factors for chronic airflow obstruction, each influencing diverse molecular and cellular pathways crucial for lung health. For instance, genes encoding detoxification enzymes, such as the Glutathione S-transferases (GSTO1, GSTO2, GSTM2, GSTT1, GSTT2) and Microsomal epoxide hydrolase (EPHX1), are vital for protecting lung cells from oxidative stress and environmental toxins. [2] Variations within these genes can compromise the body's capacity to neutralize harmful compounds, thereby increasing vulnerability to lung damage and disease progression.
Beyond detoxification, genes involved in inflammation and tissue remodeling are also critical. The SERPINE2 gene, a member of the serpin family, has been associated with Chronic Obstructive Pulmonary Disease and likely plays a role in regulating protease activity and the turnover of the extracellular matrix. [2] Other candidate genes include those modulating immune responses, such as IL10 and IL8RA, which are involved in inflammatory signaling pathways, and ADRB2, a receptor important for airway smooth muscle function. [2] Additionally, the TGFB1 gene, which encodes transforming growth factor-beta 1, is another key biomolecule associated with COPD, influencing cell growth, differentiation, and repair processes, and its dysregulation can contribute to pathological lung remodeling. [2]
Cellular Responses and Inflammatory Pathways
At the cellular level, the pathogenesis of emphysema is characterized by a complex interplay between various immune and structural cells, largely driven by chronic inflammation. Alveolar macrophages, for example, are crucial immune cells residing in the lung that become activated by stimuli like cigarette smoke, leading to the sustained production of both pro-inflammatory and anti-inflammatory cytokines and chemokines. [24] This activation initiates and sustains the inflammatory cascade, recruiting other immune cells and contributing to the release of destructive enzymes. The IL6 pathway is particularly relevant in this context, as it mediates inflammatory processes that are closely associated with observed lung function phenotypes. [2]
Oxidative stress, frequently induced by exposure to cigarette smoke, represents a major molecular pathway contributing to cellular damage in emphysema. Enzymes such as extracellular superoxide dismutase (SOD3) are essential for neutralizing reactive oxygen species, thereby protecting lung tissues from oxidative injury. [2] Genetic variations in SOD3 can impair its protective function, consequently enhancing susceptibility to oxidative damage, subsequent inflammation, and tissue destruction. [2] Furthermore, the CHI3L1 gene, which codes for the protein YKL-40, is associated with lung function and asthma risk, indicating its involvement in inflammatory and remodeling processes within the pulmonary system. [25]
Extracellular Matrix Breakdown and Repair Impairment
The structural integrity and mechanical properties of lung tissue are critically dependent on the extracellular matrix (ECM), a complex network of proteins providing support and regulating cellular functions. A pivotal pathophysiological process in emphysema is the severe imbalance between proteases, enzymes responsible for breaking down the ECM, and antiproteases, which inhibit their activity. [2] Alpha-1-antitrypsin (SERPINA1) is a well-known antiprotease whose genetic deficiency is a significant risk factor for severe, early-onset COPD and emphysema, resulting in uncontrolled proteolytic activity and the destruction of elastic fibers essential for lung recoil. [2]
Matrix metalloproteinases (MMP1, MMP9) are key enzymes involved in ECM degradation, and their elevated activity in the inflamed lung contributes to the breakdown of collagen and elastin, which are fundamental components of alveolar structure. [2] The COL4A4 gene, encoding a subunit of Type IV collagen, is also relevant, as defects in Type IV collagen genes are known to compromise structural integrity, potentially impacting the delicate basement membranes of the alveoli. [2] The chronic inflammatory environment not only promotes the relentless degradation of the ECM but also impairs effective repair mechanisms, leading to persistent tissue damage and the characteristic architectural changes observed in emphysema. [2]
Pathways and Mechanisms
Emphysema is characterized by the irreversible enlargement of airspaces distal to the terminal bronchioles, accompanied by destruction of their walls. The development and progression of emphysema involve intricate molecular pathways and cellular mechanisms, often influenced by genetic predispositions and environmental exposures. Understanding these pathways provides insight into the pathogenesis of the disease and potential therapeutic targets.
Inflammatory and Immune Signaling Pathways
Chronic inflammation is a central driver in the pathogenesis of emphysema, orchestrated by complex signaling pathways involving various cytokines and receptors. The IL6 pathway, for instance, is recognized as a mediator of inflammatory processes and is relevant to lung function phenotypes. [2] Pro-inflammatory cytokines like IL6 and those signaling through IL8RA (interleukin-8 receptor alpha) contribute to the recruitment and activation of immune cells, exacerbating tissue damage. Polymorphisms in genes such as IL4 and IL13 have also been identified in association with chronic obstructive pulmonary disease (COPD), suggesting their role in modulating inflammatory responses. [26]
Conversely, regulatory and anti-inflammatory pathways attempt to modulate this destructive inflammation. Interleukin-10, encoded by IL10, is known for its anti-inflammatory properties, and genetic polymorphisms in this gene may influence the balance of immune responses in the lung . [2], [26] The transforming growth factor-beta1 (TGFB1) gene is also associated with COPD . [2], [27] TGFB1 plays a dual role, participating in both inflammatory regulation and tissue repair processes, and its dysregulation can contribute to aberrant remodeling and fibrosis in the lung.
Oxidative Stress Response and Detoxification
The lungs are constantly exposed to oxidative challenges from environmental factors like smoke and pollutants, as well as endogenous metabolic processes. Mechanisms for handling oxidative stress and detoxifying harmful compounds are crucial for maintaining lung health. Glutathione S-transferases (GSTs), including GSTO1, GSTO2, GSTM2, GSTT1, and GSTT2, are a class of enzymes vital for detoxifying xenobiotics and products of oxidative stress. [2] Genetic variations in these Glutathione S-transferase genes can modify the rate of lung function decline in the general population, highlighting their role in metabolic regulation and catabolism of harmful substances . [28], [29]
Another key component of the antioxidant defense system is extracellular superoxide dismutase, encoded by SOD3. SOD3 neutralizes superoxide radicals, protecting lung tissues from oxidative damage. [2] Genetic associations with SOD3 have been reported in COPD, suggesting that impaired antioxidant capacity contributes significantly to the development and progression of lung destruction characteristic of emphysema. The balance between oxidant exposure and antioxidant defense mechanisms, therefore, represents a critical determinant of lung tissue integrity.
Extracellular Matrix Maintenance and Remodeling
The structural integrity of the lung, particularly the alveolar walls, depends on a delicate balance of extracellular matrix (ECM) synthesis and degradation. Disruptions to this balance are central to emphysema. The protease-antiprotease hypothesis highlights the roles of alpha-1-antitrypsin (SERPINA1) and SERPINE2 as crucial inhibitors of proteolytic enzymes that can degrade lung elastin and other ECM components. [2] A novel gene, SERPINE2, has been identified through linkage and association with COPD, underscoring its functional significance in maintaining lung architecture. [3]
Furthermore, defects in Type IV collagen genes, such as COL4A4, have been linked to impaired lung function, as these collagens are essential components of basement membranes that provide structural support to alveoli. [2] Variation in CHI3L1 affects serum YKL-40 levels, which are associated with lung function. YKL-40 is a chitinase-like protein involved in inflammation and tissue remodeling, suggesting its role in the complex processes that maintain or disrupt lung structure. [25] The constant remodeling of the ECM, influenced by these and other proteins, determines the lung's ability to resist damage and repair itself.
Genetic and Systems-Level Regulatory Mechanisms
The development of emphysema is a polygenic trait, influenced by the interplay of multiple genetic variations and their impact on interconnected biological pathways. Genetic polymorphisms in genes such as ADRB2 (beta-2 adrenergic receptor) have been associated with COPD, potentially affecting airway smooth muscle function and inflammatory responses . [2], [26] These genetic variants can alter gene regulation, protein modifications, or the efficiency of intracellular signaling cascades, thereby influencing an individual's susceptibility and disease progression.
The integration of these diverse pathways forms a complex network where pathway crosstalk and hierarchical regulation determine the emergent properties of lung health or disease. For example, chronic inflammation (IL6 pathway) can exacerbate oxidative stress, which in turn impairs the function of protease inhibitors (SERPINA1, SERPINE2), leading to increased ECM degradation. Understanding these network interactions and identifying key nodes of dysregulation, often revealed through genome-wide association studies, is crucial for pinpointing potential therapeutic targets and developing strategies to bolster compensatory mechanisms in emphysema.
Diagnostic Utility and Risk Assessment
Quantitative computed tomography (CT) imaging offers a robust method to assess the extent and distribution of emphysema, a core pathological feature of chronic obstructive pulmonary disease (COPD) that can vary widely among individuals with similar airflow obstruction. [10] These quantitative measures of emphysema, alongside airway wall thickness, are directly correlated with respiratory symptoms, providing crucial diagnostic insights beyond traditional spirometry. [8] By precisely characterizing emphysematous changes, imaging plays a vital role in identifying individuals at high risk for disease progression and informing personalized medicine strategies, particularly in vulnerable populations such as smokers and those with alpha1-antitrypsin deficiency. [10]
Prognostic Value and Disease Monitoring
Emphysema imaging carries significant prognostic value, enabling clinicians to predict disease progression, treatment response, and long-term outcomes. Longitudinal changes in quantitative emphysema, as observed through CT, are strongly associated with declines in lung function, increased COPD severity, and continued smoking, establishing imaging as a critical biomarker for disease advancement. [10] Furthermore, specific radiologic phenotypes of emphysema have been linked to the frequency of COPD exacerbations, offering valuable predictive information for acute events. [13] This detailed imaging data supports the development of more tailored monitoring strategies and potentially earlier therapeutic interventions, which is crucial given the current lack of medications that clearly ameliorate COPD progression. [10]
Associations with Comorbidities and Systemic Manifestations
Emphysema imaging is instrumental in uncovering critical associations between pulmonary pathology and various systemic comorbidities, enhancing comprehensive patient care. Radiographic emphysema has been shown to be a predictor of low bone mineral density in cohorts exposed to tobacco, highlighting a significant systemic complication of the disease. [14] Moreover, the presence of radiographic emphysema, often alongside airflow obstruction, is independently associated with an elevated risk of lung cancer. [15] Beyond these, quantitative imaging has revealed correlations between emphysema severity and arterial stiffness, and distinct patterns of emphysema distribution are linked to various clinical features, including body mass index, providing a more holistic understanding of emphysema's widespread impact on patient health. [22]
References
[1] Mannino, D. M. et al. "Chronic obstructive pulmonary disease surveillance – United States, 1971–2000." Respiratory Care, vol. 47, no. 10, 2002, pp. 1184-1199.
[2] Wilk JB et al. "Framingham Heart Study genome-wide association: results for pulmonary function measures." BMC Med Genet, 2007, 8(Suppl 1):S8.
[3] Demeo, D. L. et al. "The SERPINE2 Gene Is Associated with Chronic Obstructive Pulmonary Disease." American Journal of Human Genetics, vol. 78, no. 2, 2006, pp. 253-264.
[4] Vasan RS et al. "Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study." BMC Med Genet, 2007, 8(Suppl 1):S2.
[5] O'Donnell CJ et al. "Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study." BMC Med Genet, 2007, 8(Suppl 1):S12.
[6] Yang Q et al. "Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study." BMC Med Genet, 2007, 8(Suppl 1):S9.
[7] Melzer D et al. "A genome-wide association study identifies protein quantitative trait loci (pQTLs)." PLoS Genet, 2008, 4(5):e1000072.
[8] Grydeland TB, Dirksen A, Coxson HO, Eagan TM, Thorsen E, Pillai SG, Sharma S, Eide GE, Gulsvik A, Bakke PS. Quantitative computed tomography measures of emphysema and airway wall thickness are related to respiratory symptoms. Am J Respir Crit Care Med. 2010;181:353–359.
[9] Burrows, B., et al. "The Emphysematous and Bronchial Types of Chronic Airways Obstruction: A Clinicopathological Study of Patients in London and Chicago." Lancet, vol. 287, 1966, pp. 830–835.
[10] Kim W, et al. DSP variants may be associated with longitudinal change in quantitative emphysema. Respir Res. 2019;20(1):153.
[11] Mohamed Hoesein FAA, de Hoop B, Zanen P, Gietema H, Kruitwagen CLJJ, van Ginneken B, Isgum I, Mol C, van Klaveren RJ, Dijkstra AE, et al. CT-quantified emphysema in male heavy smokers: association with lung function decline. Thorax. 2011;66:782–787.
[12] Mair G, Miller JJ, McAllister D, Maclay J, Connell M, Murchison JT, MacNee W. Computed tomographic emphysema distribution: re-lationship to clinical features in a cohort of smokers. Eur Respir J. 2009;33:536–542.
[13] Han MK, Kazerooni EA, Lynch DA, Liu LX, Murray S, Curtis JL, Criner GJ, Kim V, Bowler RP, Hanania NA, et al.; COPDGene Investigators. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology. 2011;261:274–282.
[14] Bon J, Fuhrman CR, Weissfeld JL, Duncan SR, Branch RA, Chang C-CH, Zhang Y, Leader JK, Gur D, Greenspan SL, et al. Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am J Respir Crit Care Med. 2011;183:885–890.
[15] Wilson DO, Weissfeld JL, Balkan A, Schragin JG, Fuhrman CR, Fisher SN, Wilson J, Leader JK, Siegfried JM, Shapiro SD, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med. 2008;178:738–744.
[16] Grydeland, T. B., et al. "Quantitative Computed Tomography: Emphysema and Airway Wall Thickness by Sex, Age and Smoking." European Respiratory Journal, vol. 34, 2009, pp. 858–865.
[17] Cho, M. H., et al. "A Genome-Wide Association Study of Emphysema and Airway Quantitative Imaging Phenotypes." American Journal of Respiratory and Critical Care Medicine, vol. 192, 2015, pp. 559–569.
[18] Sin, S., et al. "A Genome-Wide Association Study of Quantitative Computed Tomographic Emphysema in Korean Populations." Scientific Reports, vol. 11, no. 1, 2021, p. 16723.
[19] Kong, X., et al. "Genome-Wide Association Study Identifies BICD1 as a Susceptibility Gene for Emphysema." American Journal of Respiratory and Critical Care Medicine, vol. 182, 2010, pp. 1242–1248.
[20] Oh, Y. M., et al. "Blood Eosinophil Count as a Prognostic Biomarker in COPD." International Journal of Chronic Obstructive Pulmonary Disease, vol. 13, 2018, pp. 3589–3596.
[21] Patel, B. D., et al. "Airway Wall Thickening and Emphysema Show Independent Familial Aggregation in Chronic Obstructive Pulmonary Disease." American Journal of Respiratory and Critical Care Medicine, vol. 178, 2008, pp. 500–505.
[22] McAllister DA, Maclay JD, Mills NL, Mair G, Miller J, Anderson D, Newby DE, Murchison JT, MacNee W. Arterial stiffness is indepen-dently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176:1208–1214.
[23] Walter, Robert E., et al. "Systemic inflammation and COPD: The Framingham Heart Study." Chest, in press.
[24] Benjamin EJ et al. "Genome-wide association with select biomarker traits in the Framingham Heart Study." BMC Med Genet, 2007, 8(Suppl 1):S11.
[25] Ober, Carole, et al. "Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function." N Engl J Med, vol. 359, no. 15, 2008, pp. 1606-1615. PMID: 18403759.
[26] Hegab, Ahmad E., et al. "Polymorphisms of IL4, IL13, and ADRB2 genes in COPD." Chest, vol. 126, no. 6, 2004, pp. 1832-1839.
[27] Celedon, Juan C., et al. "The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD)." Human molecular genetics, vol. 13, no. 15, 2004, pp. 1649-1656.
[28] Imboden, Medea, et al. "Glutathione S-transferase genotypes modify lung function decline in the general population: SAPALDIA cohort study." Respiratory research, vol. 8, no. 2, 2007.
[29] Mukherjee, Bhaswati, et al. "Glutathione S-transferase omega 1 and omega 2 pharmacogenomics." Drug metabolism and disposition: the biological fate of chemicals, vol. 34, no. 7, 2006, pp. 1237-1246.